StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate
Sanofi halted development of an oral STAT6 degrader that had been under study in a Phase I first-in-human trial in Europe. STAT6, a key drug target in type 2 inflammation, is among the five targets identified by the companies in their collaboration, launched in 2020. The post StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate appeared first on GEN - Genetic Engineering and…
Sanofi halted development of an oral STAT6 degrader that had been under study in a Phase I first-in-human trial in Europe. STAT6, a key drug target in type 2 inflammation, is among the five targets identified by the companies in their collaboration, launched in 2020. The post StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate appeared first on GEN - Genetic Engineering and…
This is a summary of the story. Read the full article at GEN — Genetic Engineering & Biotechnology News ↗